Product Information
NEOMYCIN-POLYMYXIN-HC EAR SUSP is a generic product labeled by Bausch & Lomb Incorporated, priced at $3.8331 per ML under NDC 24208063562. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Aug 28, 1996. Its Orange Book therapeutic-equivalence code is AT.
Strength
10; 3.5; 10000 mg/mL; mg/mL; [USP'U]/mL
Manufacturer
Bausch & Lomb IncorporatedNDC
24208063562
Classification
Generic
Dosage Form
SUSPENSION/ DROPS
Route
AURICULAR (OTIC)
Effective Date
9/23/2026
Active Ingredients
HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA064065FDA Approved
8/28/1996
TE Code
AT
On Market Since
8/28/1996
Pharmacological Classes
Price Statistics
The NADAC for NEOMYCIN-POLYMYXIN-HC EAR SUSP has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 102.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.8331 per ML |
|---|---|
| All-time high | $8.1994 (Jan 13, 2016) |
| All-time low | $1.8455 (Aug 19, 2015) |
| 52-week high | $4.4718 |
| 52-week low | $3.7744 |
| Median price | $5.4971 |
| Average price | $5.0323 |
| Largest weekly change | +236.1% (Sep 30, 2015) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Neomycin sulfate, Polymyxin B Sulfate and Hydrocortisone market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Neomycin sulfate, Polymyxin B Sulfate and Hydrocortisone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoglycoside Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NEOMYCIN-POLYMYXIN-HC EAR SUSP?
The current National Average Drug Acquisition Cost (NADAC) for NEOMYCIN-POLYMYXIN-HC EAR SUSP, manufactured by Bausch & Lomb Incorporated, is $3.8331 per ML (NDC 24208063562), effective Sep 30, 2026.
How has the price of NEOMYCIN-POLYMYXIN-HC EAR SUSP changed over time?
Over the history we have for it, the NADAC for NEOMYCIN-POLYMYXIN-HC EAR SUSP has risen 102.1%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for NEOMYCIN-POLYMYXIN-HC EAR SUSP?
Since Nov 28, 2013, the NADAC for NEOMYCIN-POLYMYXIN-HC EAR SUSP has ranged from a low of $1.8455 (Aug 19, 2015) to a high of $8.1994 (Jan 13, 2016), with a median of $5.4971 per ML.
Are there cheaper alternatives to NEOMYCIN-POLYMYXIN-HC EAR SUSP?
No other NADAC-published product currently shares the active ingredient and strength of NEOMYCIN-POLYMYXIN-HC EAR SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NEOMYCIN-POLYMYXIN-HC EAR SUSP?
NEOMYCIN-POLYMYXIN-HC EAR SUSP (NDC 24208063562) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a generic product.